Skip to main content

What the FDA labels say about taking them together

Methotrexate and stiripentol

Stiripentol's FDA label of April 27, 2026 names methotrexate in its drug interactions section; the methotrexate labels PlainMeds reads (4) do not name stiripentol. The stiripentol label: “Because of potential inhibition of enzyme/transporter activity, consider a reduction in dosage of substrates of CYP2C8, CYP2C19, P-gp (e.g., carbamazepine), and BCRP, if adverse reactions are experienced when …”

Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the stiripentol FDA label on DailyMed (effective April 27, 2026, BIOCODEX, INC.).

What does the methotrexate label say about stiripentol?

Methotrexate's label (effective May 27, 2026) and its 3 other brand-application labels do not name stiripentol in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed

What does the stiripentol label say about methotrexate?

Stiripentol label, drug interactions

Because of potential inhibition of enzyme/transporter activity, consider a reduction in dosage of substrates of CYP2C8, CYP2C19 (e.g., diazepam, clopidogrel), P-gp (e.g., carbamazepine), and BCRP (e.g., methotrexate, prazosin, glyburide), if adverse reactions are experienced when administered concomitantly with DIACOMIT.

Source: FDA drug label (Diacomit), BIOCODEX, INC., effective April 27, 2026 (SPL set 58304ba8-9779-4658-811e-94ffe08c3f16), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

29Methotrexate generic labelers
0Stiripentol generic labelers
MethotrexateStiripentol
Labeled forRheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancern/a
Boxed warningYesNo
Pharmacy cost (NADAC)$0.158 per tablet 2.5 mg tabletn/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?